Syncromune®, Inc. Presents Innovative SYNC-T™ Combination Immunotherapy Approach at Major European Interventional Oncology ConferenceNovel procedure combines image-guided tumor cryolysis with intratumoral immunotherapy infusion, with early clinical findings in metastatic prostate cancerFORT LAUDERDALE, Fla., April 29, 2026 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company advancing SYNC-T™, an investigational platform...